Table 2: Summary of the CD4 T cell responses to the Sp17 peptides by DLBCL patients.

PatientsMHC class II statusSp17 protein -IFN response to peptides per 50,000 cells
Sp17(4)Sp17(5)Sp17(6)No peptideHIV-1PHA

Significant response
1DRB0102,1104+
2DRB0101,0701+
5DRB0301,0401
8DRB1501,0803ND
10DRB0101ND
12DRB0401,1401+
14DRB1403,0401ND
18DRB0401,0401+
No significant response
7DRB0301,0701+
9DRB0301,1601
15DRB1301,1101ND
19DRB0401,0901+
20DRB1104,1501+
21DRB0301,1303+
39DRB0701
43DRB0101,1101
48DRB0101,0405

DLBCL(dn): de novo diffuse large B cell lymphoma; DLBCL(t): diffuse large B cell lymphoma transformed; TCR: T cell rich B cell lymphoma. The results +/− are from triplicate ELISPOT cultures. The SD was calculated using standard techniques. Significant -IFN responses are highlighted in bold. ND, not determined.